Novartis CAR-T Therapy Drug Recommended by FDA PanelZacks.comEarlier in 2017, Novartis submitted its Biologics License Application (BLA) for CTL019 to the FDA, marking the first submission by Novartis for a CAR-T cell therapy. We remind investors that … Continue reading
Immunotherapy for lung cancer leads to hair repigmentationHealioPatients with lung cancer who were received immunotherapy experienced hair repigmentation, with the majority also experiencing good clinical response, according to recently published study… Continue reading
Gizmodo |
Did an FDA Panel Really Just Approve the First Gene Therapy Treatment?
Gizmodo This week marked a major milestone in medicine: On Wednesday, a Food and Drug Administration panel unanimously recommended the approval of the first CAR-T therapy, a pioneering new cancer drug from Novartis that genetically engineers a patient’s … CAR-T gene therapy for leukemia clears FDA hurdleCBS News Gene therapy as cancer treatment — ‘a true living drug’ — gets FDA endorsementChicago Tribune FDA Panel OKs First Gene Therapy For LeukemiaWebMD USA TODAY –CNET –CNBC –New York Times all 184 news articles » |
CBS Local |
Dog Gets Special Stem Cell Treatment To Relieve Pain
CBS Local MediVet’s stem cell therapy surpasses any other treatment options for elbow or hip dysplasia and arthritis in dogs and cats. Stem cells rebuild the cartilage in joints and reduce painful inflammation naturally. They are healing cells, naturally found … |
CBS Local |
Dog Gets Special Stem Cell Treatment To Relieve Pain « CBS Denver
CBS Local A dog received stem cell treatment at the Aspen Arbor Animal Hospital in Broomfield on Wednesday. |
Newsroom |
‘We’ve reached peak antibiotics’
Newsroom “Taking advantage of the fact that bacteria are so good at swapping bits of DNA, we and others have shown that you can employ ‘synthetic biology‘ approaches to transfer these blueprints to a new host – a bacterium that we can grow in the lab – and a … |
|
Discussing The Future Of CRISPR-Cas: Gene Editing Takes Center Stage At CRISPRcon
SYS-CON Media (press release) “Fulfilling the promise and the potential of CRISPR technology requires collaboration and thoughtful, open dialogue,” says Jennifer Doudna, professor at the University of California, Berkeley, and a pioneer in the field of CRISPR biology and genome … |